Department of Nephrology, Xijing Hospital, Fourth Military Medical University, No. 17 West Changle Road, Xi'an, Shaanxi Province, China.
Cytokine. 2010 May;50(2):186-91. doi: 10.1016/j.cyto.2010.02.005. Epub 2010 Mar 3.
The aim of this study was to investigate the impacts of continuous veno-venous hemofiltration (CVVH) on plasma cytokines and monocyte human leukocyte antigen-DR (HLA-DR) expression and to evaluate the relationship between them during CVVH treatment in septic patients. Forty septic patients were enrolled in this study. They were randomly divided into control group (who received conventional treatment, n=20) and CVVH group (who received conventional treatment and CVVH treatment, n=20). The blood samples were taken to measure the changes of plasma cytokines (IFN-gamma, TNF-alpha, IL-1, IL-2, IL-4, IL-6, IL-10 and IL-13) and HLA-DR expression on monocytes. After CVVH treatment, the plasma levels of IFN-gamma, IL-1, IL-2, IL-4, IL-10 and IL-13 in septic patients were markedly decreased (P<0.05), while the levels of TNF-alpha and IL-6 were only lowered to some extent without significant difference (P>0.05). HLA-DR expression on monocytes improved in CVVH treated patients (P<0.05). No matter pre-treatment or post-treatment of CVVH, there was a negative correlation between plasma IL-10 and monocyte HLA-DR expression (P<0.05). In contrast, no obvious change was shown in control patients. Our findings suggest that CVVH is effective in removal of many plasma cytokines and in improvement of monocyte HLA-DR expression in septic patients.
本研究旨在探讨连续性静脉-静脉血液滤过(CVVH)对脓毒症患者血浆细胞因子和单核细胞人类白细胞抗原-DR(HLA-DR)表达的影响,并评估它们在 CVVH 治疗过程中的关系。
将 40 例脓毒症患者纳入本研究,随机分为对照组(接受常规治疗,n=20)和 CVVH 组(接受常规治疗和 CVVH 治疗,n=20)。采集血样以测量血浆细胞因子(IFN-γ、TNF-α、IL-1、IL-2、IL-4、IL-6、IL-10 和 IL-13)和单核细胞 HLA-DR 表达的变化。
CVVH 治疗后,脓毒症患者血浆中 IFN-γ、IL-1、IL-2、IL-4、IL-10 和 IL-13 的水平显著降低(P<0.05),而 TNF-α和 IL-6 的水平仅降低到一定程度,无显著差异(P>0.05)。CVVH 治疗患者单核细胞 HLA-DR 表达改善(P<0.05)。
无论在 CVVH 治疗前还是治疗后,血浆 IL-10 与单核细胞 HLA-DR 表达之间均呈负相关(P<0.05)。相比之下,对照组患者没有明显变化。
我们的研究结果表明,CVVH 可有效清除脓毒症患者多种血浆细胞因子,并改善单核细胞 HLA-DR 表达。